Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

NCT00492206 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Cetuximab

Sponsor

University of Pittsburgh

Collaborators

[object Object]